<DOC>
	<DOC>NCT00504127</DOC>
	<brief_summary>To study of efficacy and safety of Naproxcinod vs. Naproxen and Placebo in the indication of signs and symptoms of osteoarthritis</brief_summary>
	<brief_title>Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee</brief_title>
	<detailed_description>This is a 53 week study consisting in a 26 week randomized, double-blind, parallel group, multicenter study comparing efficacy and safety of Naproxcinod, Placebo and Naproxen. The first 26 weeks will be followed by a naproxen-controlled treatment period up to 52 weeks and a 1-week post-treatment safety follow-up.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Naproxen-n-butyl nitrate</mesh_term>
	<criteria>Men and Woman (40 or older) with a diagnosis of primary OA of the knee. Must be a current chronic user of NSAIDS or acetaminophen Must discontinue all analgesic therapy at Screening Uncontrolled Hypertension or Diabetes Hepatic or Renal Impairment Current or expected use of anticoagulant Clinical relevant abnormal ECG A history of alcohol or drug abuse Candidates for imminent joint replacement Participation within 30 days prior to screening in another investigational study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Degenerative</keyword>
</DOC>